Navigation Links
Neurocrine Biosciences To Present At Oppenheimer's 24th Annual Healthcare Conference
Date:12/4/2013

SAN DIEGO, Dec. 4, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Oppenheimer's 24th Annual Healthcare Conference in New York City.  

The live presentation takes place on Wednesday, December 11 at 10:40am ET (7:40am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development. Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet a
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Regado Biosciences, Inc. ... on the Phase 3 clinical development of Revolixys™ Kit ... drug system, today announced that it will hold a ... 12, 2014, at 8:30 a.m. EDT to discuss its ... Interested participants and investors may access the conference ...
(Date:7/29/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... healthcare conferences during the third quarter, the 2014 Avondale ... Healthcare 2014 Conference.  Alexza,s corporate presentation will be webcast ... each event are below: , 2014 Avondale ... Boston , MA.  The format is ...
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... , MIAMI , July 21 Understanding ... patient resources. That,s why Puerto Rican actress, author and mother ... partnered with the Asthma and Allergy Foundation of America (AAFA) ... new Spanish asthma education web resource to help patients learn ...
... Trinity Orthopedics LLC, a medical device company that develops and markets ... a Notice of Allowance from the U.S. Patent and Trademark Office for ... posterior fixation system in the United States under the ReStor ... "Recent clinical studies ...
Cached Medicine Technology:Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 2Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 3Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 4Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 5Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 6Trinity Orthopedics Receives Patent Allowance for Sagittally Stable Spinal Fixation System 2
(Date:7/29/2014)... July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. , The study finds ...
(Date:7/29/2014)... By Dennis Thompson ... -- Exercise, a healthy diet and good sleep can protect ... down the aging process at a cellular level, researchers report. ... stressful events are linked to increased shortening of telomeres, the ... quickly cells age. "We found that over a one-year ...
(Date:7/29/2014)... 2014 During his 37 years in dental ... Associates, has had a steady stream of college students shadow ... have now gone on to dental school and some are ... shadowing program helps college students find success. , For students ... them the chance to see a realistic view of what ...
(Date:7/29/2014)... Medicine researchers have made an important advancement toward ... deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). , ... a steady rise in the incidence of human ... the need for a vaccine critical. Successful vaccine ... prevent disease, and the VCU team has identified ...
(Date:7/29/2014)... Boise, Idaho (PRWEB) July 29, 2014 ... & Hart LLP ’s Boise office, has been appointed ... Cross of Greater Idaho. , Busacker is an experienced ... executive compensation matters. He advises clients on a wide ... plan design, plan administration, compliance, and governance concerns. His ...
Breaking Medicine News(10 mins):Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2
... (cell culture) research currently underway at the Peninsula Medical School ... and develop therapies for the treatment of multiple tumours in ... a protein called merlin, which in turn cause cancers in ... brain. Schwann cells produce the sheaths that surround and insulate ...
... Makes First Investment in Antibacterial Therapeutics From ... its Biodefense and Pandemic ... today,announced the close of a $30 million Series B financing ... now completing Phase I testing. The financing was led by ...
... Group Calls for Funding Suspension After Trial ... a Baltimore Sun,opinion piece today ( http://www.baltimoresun.com/news/opinion/oped/bal ... suspension of costly HIV vaccine research funding ... proven HIV/AIDS prevention,testing and treatment strategies., ...
... take their lives in the spring, doctors say , , SUNDAY, March ... time of renewal and hope, the greatest number of suicides in ... the American College of Emergency Physicians. , It,s not clear why ... L. Lawrence. But "we do know that suicide is the 11th ...
... Music therapy can help reduce anxiety and improve physical ... everyone has used music at one time or another ... discipline of music therapy takes the use of music ... "Music therapy is an evidence-based practice that can affect ...
... YORK, March 21 Americans with ... their Medicare Advantage Plan have an ... to this report from UnitedHealthcare at:, ... access video, audio, text, graphics and,photos ...
Cached Medicine News:Health News:Research to lead to brain tumor therapies 2Health News:Research to lead to brain tumor therapies 3Health News:Trius Raises $30 Million in Series B Financing 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 3Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 4Health News:Know Suicide's Warning Signs 2Health News:Know Suicide's Warning Signs 3Health News:Music as Medicine 2Health News:Music as Medicine 3
Bi-phasic peristaltic infusion pump for tumescent work....
... a compact system featuring,easy setup and flow ... allowing the use of less,expensive disposable tubing ... office or hospital use, the,PSI-TEC III Infiltrator ... - 5" (w) X 8" (l) X ...
... represents a major advance in the ... procedures. Combined with precision fluid management, ... solid grooved probe design and patented ... been designed to minimize trauma to ...
Inquire...
Medicine Products: